Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PSB205 |
Synonyms | |
Therapy Description |
PSB205 comprises the combination of a monoclonal antibody targeting CD274 (PD-L1) and a monoclonal antibody CTLA4, which has potential anti-tumor activity (J Clin Oncol 40, 2022 (suppl 16; abstr 2611)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PSB205 | PSB-205|PSB 205|QL-1706|QL 1706|QL1706 | CTLA4 Antibody 31 PD-L1/PD-1 antibody 121 | PSB205 comprises the combination of a monoclonal antibody targeting CD274 (PD-L1) and a monoclonal antibody CTLA4, which has potential anti-tumor activity (J Clin Oncol 40, 2022 (suppl 16; abstr 2611)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |